Literature DB >> 27421225

The pathogenic mechanism of dysbindin-1B toxic aggregation: BLOC-1 and intercellular vesicle trafficking.

Wei Yang1, Chunyan Zhu1, Yan Shen1, Qi Xu2.   

Abstract

DTNBP1, which encodes dysbindin-1, is associated with cognitive impairment. Genetic evidence indicates that the C allele of rs117610176 leads to an increase in DTNBP-1b mRNA splicing in patients with paranoid schizophrenia. In addition, dysbindin-1B, rather than dysbindin-1A/C, exhibits a tendency toward toxic aggregation. In postmortem brains, dysbindin-1B not only aggregates with itself, it also co-aggregates with proteins that interact with it. However, the pathogenic mechanism underlying dysbindin-1B toxic aggregation remains unknown. In the brain, dysbindin-1 is primarily found as a subunit of biogenesis of lysosome-related organelles complex 1 (BLOC-1), which plays a role in intracellular vesicle trafficking. Therefore, we hypothesized that dysbindin-1B might impair the cognitive function of schizophrenia patients by co-aggregating with BLOC-1 subunits and disturbing the function of BLOC-1. In this study, we investigated the dominant-negative effect of dysbindin-1B on the BLOC-1 complex. We found that in multiple brain areas in Dys1B(+/+) mice, the expression levels of soluble functional BLOC-1 subunits were decreased. Meanwhile, BLOC-1 subunits co-aggregated with dysbindin-1B-myc. Functional studies in primary cortical neurons further revealed the malfunction of BLOC-1 in intercellular vesicle trafficking in Dys1B(+/+) mice. In addition, we used the Morris water maze task to investigate the effects of dysbindin-1B aggregation on cognition. The results demonstrated that Dys1B(+/+) mice exhibited spatial learning and memory deficits, which were accompanied by the shrinkage of apical and basal dendritic branches and the loss of dendritic spines in hippocampal CA1 neurons, as demonstrated by Golgi staining. Taken together, the results of the present study suggest that dysbindin-1B toxic aggregation might impair cognition through a dominant-negative effect on BLOC-1.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  BLOC-1; cognitive impairment; dysbindin-1; intercellular vesicle trafficking; protein aggregation

Mesh:

Substances:

Year:  2016        PMID: 27421225     DOI: 10.1016/j.neuroscience.2016.07.008

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  5 in total

1.  Dysbindin-1 contributes to prefrontal cortical dendritic arbor pathology in schizophrenia.

Authors:  Glenn T Konopaske; Darrick T Balu; Kendall T Presti; Grace Chan; Francine M Benes; Joseph T Coyle
Journal:  Schizophr Res       Date:  2018-05-11       Impact factor: 4.939

2.  An unpredicted aggregation-critical region of the actin-polymerizing protein TRIOBP-1/Tara, determined by elucidation of its domain structure.

Authors:  Nicholas J Bradshaw; Antony S K Yerabham; Rita Marreiros; Tao Zhang; Luitgard Nagel-Steger; Carsten Korth
Journal:  J Biol Chem       Date:  2017-04-24       Impact factor: 5.157

Review 3.  Protein misassembly and aggregation as potential convergence points for non-genetic causes of chronic mental illness.

Authors:  Nicholas J Bradshaw; Carsten Korth
Journal:  Mol Psychiatry       Date:  2018-08-08       Impact factor: 15.992

4.  Retinal biomarkers and pharmacological targets for Hermansky-Pudlak syndrome 7.

Authors:  Giovanni Luca Romano; Chiara Bianca Maria Platania; Gian Marco Leggio; Sebastiano Alfio Torrisi; Salvatore Giunta; Salvatore Salomone; Michele Purrello; Marco Ragusa; Cristina Barbagallo; Frank J Giblin; Rosa Mastrogiacomo; Francesca Managò; Maurizio Cammalleri; Francesco Papaleo; Filippo Drago; Claudio Bucolo
Journal:  Sci Rep       Date:  2020-03-04       Impact factor: 4.379

Review 5.  Developmental Genes and Regulatory Proteins, Domains of Cognitive Impairment in Schizophrenia Spectrum Psychosis and Implications for Antipsychotic Drug Discovery: The Example of Dysbindin-1 Isoforms and Beyond.

Authors:  John L Waddington; Xuechu Zhen; Colm M P O'Tuathaigh
Journal:  Front Pharmacol       Date:  2020-01-29       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.